LoadingLoadingLoading31 funds hold it.Insiders net selling.
Net selling: insiders sold $521K and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $5K to $75K in total in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 3, 2026
Financial period
Q3 2026
Earnings per share
$5.78 expected
Revenue
$10.07B expected
FY 2026 guidance
$38.90B to $39.70B
No comparable estimate
Estimates as of Nov 9, 2026
EPS expected
$5.31 to $6.10
Revenue expected
15 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 3, 2026 | $6.45est. $5.78 | +11.55%beat | $10.40Best. $10.07B+3.30% | +8.8%from $9.56B |
| Jun 30, 2026Reported Aug 4, 2026 | $6.29est. $5.62 | +11.97%beat | $10.05BCompany release | +9.5%from $9.18B |
| Mar 31, 2026Reported Apr 30, 2026 | $5.15est. $4.77 | +8.04%beat | $8.62BSEC filing | +5.8%from $8.15B |
| Dec 31, 2025Reported Feb 3, 2026 | $5.29est. $4.73 | +11.94%beat | $9.90BAlpha Vantage | +8.9%from $9.09B |
| Sep 30, 2025Reported Nov 4, 2025 | $5.64est. $5.01 | +12.57%beat | $9.56BSEC filing | +12.4%from $8.50B |
| Jun 30, 2025Reported Aug 5, 2025 | $6.02est. $5.28 | +14.02%beat | $9.18BSEC filing | +9.4%from $8.39B |
| Mar 31, 2025Reported May 1, 2025 | $4.90est. $4.26 | +15.02%beat | $8.15BSEC filing | +9.4%from $7.45B |
| Dec 31, 2024Reported Feb 4, 2025 | $5.31est. $5.08 | +4.53%beat | $9.09BAlpha Vantage | +10.9%from $8.20B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $9.90B | $8.62B | $10.05B | $10.37B |
| Cost of what it sold | $1.79B | $2.74B | $2.81B | $2.79B |
| Gross profit | $8.11B | $5.87B | $7.24B | $7.58B |
| What it spent | ||||
| Research and development | $2.15B | $1.72B | $1.87B | $2.11B |
| Sales and admin | $1.95B | $1.60B | $1.75B | $1.68B |
| Other operating costs | $61.0M | -$113.0M | $116.0M | $76.0M |
| Total operating expenses | $4.16B | $3.21B | $3.73B | $3.87B |
| What was left | ||||
| Operating profit | $3.94B | $2.67B | $3.51B | $3.71B |
| Interest on debt | $653.0M | $657.0M | $673.0M | $653.0M |
| Profit before tax | $1.51B | $2.08B | $2.77B | $4.69B |
| Tax | $181.0M | $265.0M | $393.0M | $822.0M |
| Net profit | $1.33B | $1.82B | $2.38B | $3.86B |
| EBITDA | $3.30B | $3.86B | $4.55B | $6.46B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
BullishNov 9Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028
NeutralNov 9Roivant Sciences Q2 2027 Earnings Call Transcript
Leans bullishNov 9Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
NeutralNov 9Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Leans bullishNov 9Icelandic Genetics Helped Shape Amgen’s MariTide Drug
BullishNov 9Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
BullishNov 9The Strong Earnings Posted By Neurocrine Biosciences (NASDAQ:NBIX) Are A Good Indication Of The Strength Of The Business
NeutralNov 930 macro signals shaping AMGN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
